

13th December, 2017

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata - 700 001

To,
Dy. General Manager,
Corporate Relationship Department,
BSE Limited,
P. J. Tower,
Mumbai - 400 001

Sub: - Outcome of Board Meeting

Scrip Code: 10012130 (CSE Limited) & 590088 (BSE Limited)

Dear Sir,

Pursuant to Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the meeting of the Board of Directors of the Company held at its Registered Office of the Company on Wednesday, 13th December, 2017 (which commenced at 11.00 A.M. and concluded at 1.55 P.M.) wherein they have approved the following :-

1. Unaudited Financial Results for the 2nd quarter ended 30th September, 2017 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. Limited Review Report by the Statutory Auditors on Unaudited Financial Result for the 2nd Quarter ended 30th September, 2017.

The above information is also available on Company's website www.adinathbio.com and on the Stock exchange website: www.cse-india.com and www.bseindia.com.

We request you to take on record and acknowledge the same.

Thanking you,
For Adinath Bio-Labs Limited


Kishan Singh
Whole time Director
DIN: 07526266



Encl. As Above

Email: investors@adinathbio.com
<http://www.adinathbio.com>

4, N. S. Road, 1st Floor, Kolkata - 700 001
Telephone: +91-33-22315718

Statement of Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2017						
PART I						
Sl. No.	Particulars	3 months ended (30/09/2017)	Preceding 3 months ended (30/06/2017)	Corresponding 3 months ended in previous year (30/09/2016)	Year to date figures for current year ended (30/09/2017)	Year to date figures for previous year ended (30/09/2016)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1	Income from operations					
	(a) Net Sales / income from operations	-	11,22,670	15,59,988	11,22,670	34,70,558
	(b) Other Income	1,20,000	-	-	1,20,000	-
	Total income from operations (net)	1,20,000	11,22,670	15,59,988	12,42,670	34,70,558
2	Expenses					
	(a) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	(b) Employee benefits expense	1,90,050	3,53,354	5,72,862	5,43,404	11,88,147
	(c) Finance Cost	-	-	-	-	-
	(d) Depreciation and amortisation expense	2,14,017	2,12,015	2,86,195	4,26,032	5,72,390
	(e) Other expenses	3,88,455	5,29,398	6,00,427	9,17,853	14,91,460
	Total expenses	7,92,522	10,94,767	14,59,484	18,87,289	32,51,997
3	Profit / (Loss) from operations before Exceptional & Extraordinary Items (1-2)	(6,72,522)	27,903	1,00,504	(6,44,619)	2,18,561
4	Exceptional & Extraordinary Items	-	-	-	-	-
5	Profit / (Loss) before Tax (3 ± 4)	(6,72,522)	27,903	1,00,504	(6,44,619)	2,18,561
6	Tax expense					
	Current Tax	-	-	-	-	-
	Deferred Tax	-	-	-	-	-
	Earlier Years	-	-	-	-	-
	Total Tax Expenses	-	-	-	-	-
7	Net Profit/(Loss) after tax(5 ± 6)	(6,72,522)	27,903	1,00,504	(6,44,619)	2,18,561
8	Other Comprehensive Income / (Loss)	-	-	-	-	-
9	Total Comprehensive Income / (Loss) (7 ± 8)	(6,72,522)	27,903	1,00,504	(6,44,619)	2,18,561
10	Paid-up equity share capital (Face Value of the Share shall be indicated)(B)	22,07,42,560	22,07,42,560	22,07,42,560	22,07,42,560	22,07,42,560
		1	1	1	1	1
11	Earnings Per Share (not annualised):					
	Basic & Diluted	(0.00)	0.00	0.00	(0.00)	0.00



Email: investors@adinathbio.com
<http://www.adinathbio.com>

4, N. S. Road, 1st Floor, Kolkata – 700 001
 Telephone: +91-33-22315718

Statement of Unaudited Assets and Liabilities as on 30th September, 2017

Sl. No.	Particulars	As at 30th September, 2017
I	ASSETS	
A	Non-current assets	
	a) Property, plant and equipment	39,93,093
	b) Capital work-in-progress	1,86,56,065
	c) Intangible assets	-
	d) Financial assets	
	i) Investments	53,87,499
	ii) Loans and Advances	7,92,60,000
	iii) Other Non current financial assets	3,68,92,695
	e) Other non-current assets	-
	f) Deferred tax assets (net)	-
	Total Non-current assets	14,41,89,352
B	Current assets	
	a) Inventories	70,38,265
	b) Financial assets	
	i) Trade receivable	60,63,427
	ii) Cash and cash equivalents	2,87,209
	iii) Loans and Advances	-
	iv) Other current financial assets	72,000
	c) Other current assets	-
	d) Prepayments	-
	Total Current assets	1,34,60,901
	TOTAL ASSETS	15,76,50,253
II	EQUITY AND LIABILITIES	
A	EQUITY	
	a) Equity Share capital	22,07,42,560
	b) Other Equity	(6,48,49,768)
	Total equity	15,58,92,792
B	LIABILITIES	
I	Non-current liabilities	
	a) Financial liabilities	
	i) Borrowings	-
	ii) Other non-current financial liabilities	-
	Total Non-current liabilities	-
II	Current liabilities	
	a) Financial liabilities	
	i) Borrowings	-
	ii) Trade payables	-
	iii) Other current financial liabilities	-
	b) Other current liabilities	4,07,483
	c) Provisions	45,900
	d) Current tax liabilities	13,04,078
	Total Current liabilities	17,57,461
	TOTAL EQUITY AND LIABILITIES	15,76,50,253



Notes:

- The above Unaudited Financial results have been reviewed by the Audit committee at their meeting held on 12th December, 2017 and adopted by the Board of Directors at their meeting held on 13th December, 2017.
- The results are based on the financial statements prepared by the Company's management in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder. Beginning with 01st April, 2017, the Company has for the first time adopted Ind AS with the transition date of 01st April, 2016. The financial results are made available on the company's website www.adinathbio.com. Financial Results of all the periods presented have been prepared in accordance with the recognition and the measurement principles of IND AS-34 (Interim Financial Reporting).
- The Company is engaged in the business of Trading in Commodities and its allied products and therefore has only one reportable segment as envisaged by Ind AS 108 'Operating Segment'.
- The Statutory Auditors of the Company have conducted a limited review of the above unaudited standalone financial results of the Company for the quarter and half year ended September 30, 2017 and issued an unqualified report in this behalf.

The figures for the corresponding quarter and half year ended 30 September 2016, including the reconciliation of profit under Ind-AS of the corresponding quarter/period with the profit reported under previous GAAP (as stated above), have not been subjected to limited review. The management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.

- Provisions for taxations will be made at the end of the year.
- The statement does not contain Ind AS compliant results for the previous year ended March 31, 2017 as the same is not mandatory as per SEBI circular CIR/CFD/FAC/62/2016 dated 05th July, 2016.
- Reconciliation of Profit, as previously reported under IGAAP to Ind-AS for the quarter and half year ended on 30th September 2016 is given below:

Particulars	Corresponding months ended in the previous year September 30, 2016	Corresponding half year ended on September 30, 2016
Net Profit/ (Loss) for the quarter under previous Indian GAAP	1,00,504	2,18,561
Add/ (Less): Adjustments with respect to Ind AS compliance	-	-
Net Profit/ (Loss) for the quarter under IND AS	1,00,504	2,18,561


The reconciliation statement has been provided in accordance with circular CIR/CFD/FAC/62/2016 issued by SEBI dated July 05, 2016 on account of implementation of Ind-AS by listed companies.

- Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period's classification / disclosure.

Date: 13th December, 2017
Place: Kolkata



By order of the Board
For Adinath Bio-Labs Limited



Kishan Singh
Whole-Time Director
DIN No.: 07526266

Email: investors@adinathbio.com
<http://www.adinathbio.com>

4, N. S. Road, 1st Floor, Kolkata – 700 001
Telephone: +91-33-22315718

Limited Review Report on quarterly Unaudited Financial Results of Adinath Bio-Labs Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To the Board of Directors of
Adinath Bio-Labs Limited**

We have reviewed the accompanying Statement of Unaudited Financial Results ('the Statement') of Adinath Bio-Labs Limited ("the Company") for the quarter and six months period ended 30 September, 2017 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016. Attention is drawn to the fact that the figures for the corresponding quarter and six months period ended 30 September 2016 including the reconciliation of profit under Ind AS of the corresponding quarter / period with profit reported under previous GAAP, as reported in these financial results have been approved by the Company's Board of Directors but have not been subjected to review.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 13 December, 2017. Our responsibility is to issue a Report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' ('the Standard'), issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with applicable Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Mohindra Arora & Co.
Chartered Accountants
Firm registration No: 006551N



Ashok Katial
Partner
Membership No: 09096

Place : Mumbai
Date : December 13, 2017